CDK9 and ovarian carcinoma: Wang et al. [14] found that the expression level of CDK9 in metastatic and recurrent ovarian cancer tissues was significantly higher than that in tumor tissues with primary lesions, and the disease-free survival and total survival time of CDK9 positive group were significantly lower compared with that of CDK9 negative group.